Cargando…
Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures
PURPOSE: The Second Multidisciplinary Forum: Parathyroid Hormone (PTH) Use in Osteoporotic Patients at High Risk for Fractures (HRF) was conducted to identify specific findings that would be helpful for defining high-risk status and guiding the use of parathyroid hormone 1–84 (PTH1-84) as an anaboli...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585953/ https://www.ncbi.nlm.nih.gov/pubmed/23193980 http://dx.doi.org/10.2165/11641360-000000000-00000 |
_version_ | 1782261243741995008 |
---|---|
author | Gimeno, Esteban Jódar |
author_facet | Gimeno, Esteban Jódar |
author_sort | Gimeno, Esteban Jódar |
collection | PubMed |
description | PURPOSE: The Second Multidisciplinary Forum: Parathyroid Hormone (PTH) Use in Osteoporotic Patients at High Risk for Fractures (HRF) was conducted to identify specific findings that would be helpful for defining high-risk status and guiding the use of parathyroid hormone 1–84 (PTH1-84) as an anabolic therapy in daily clinical practice. This article summarizes the conclusions from the meeting. MATERIALS AND METHODS: Based on three typical case records, and the final conclusions from the first Forum (held in 2010), several questions were posed regarding daily clinical practice definitions of HRF and use of PTH1-84, through a series of 19 meetings throughout Spain. The main discussion topics and agreed conclusions were collected by meeting coordinators and shared at a meeting held in May 2011. After extensive discussions, which also included other organizational and educational matters, some newly agreed conclusions were reached. RESULTS: The consensus was that an HRF patient is usually thought of as being elderly (aged >70 years), with a very low bone mass or a prevalent fracture, and some other associated risk factors. High-risk groups who were identified included patients with neurologic diseases, institutionalized individuals, and patients receiving long-term steroid therapy. PTH1-84 was considered a safe and effective drug, having added value because of its analgesic effect and good level of patient adherence. Opportunities for improved PTH1-84 use were identified, such as better patient selection and follow-up based on localization and specialty. Some improvement opportunities were also detected in organizational and educational areas. CONCLUSION: The Forum identified differences between clinical recommendations and daily clinical practice. Some elements, involving both organizational and educational areas that could help to reduce such discrepancies, are described. |
format | Online Article Text |
id | pubmed-3585953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-35859532013-03-07 Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures Gimeno, Esteban Jódar Drugs R D Original Research Article PURPOSE: The Second Multidisciplinary Forum: Parathyroid Hormone (PTH) Use in Osteoporotic Patients at High Risk for Fractures (HRF) was conducted to identify specific findings that would be helpful for defining high-risk status and guiding the use of parathyroid hormone 1–84 (PTH1-84) as an anabolic therapy in daily clinical practice. This article summarizes the conclusions from the meeting. MATERIALS AND METHODS: Based on three typical case records, and the final conclusions from the first Forum (held in 2010), several questions were posed regarding daily clinical practice definitions of HRF and use of PTH1-84, through a series of 19 meetings throughout Spain. The main discussion topics and agreed conclusions were collected by meeting coordinators and shared at a meeting held in May 2011. After extensive discussions, which also included other organizational and educational matters, some newly agreed conclusions were reached. RESULTS: The consensus was that an HRF patient is usually thought of as being elderly (aged >70 years), with a very low bone mass or a prevalent fracture, and some other associated risk factors. High-risk groups who were identified included patients with neurologic diseases, institutionalized individuals, and patients receiving long-term steroid therapy. PTH1-84 was considered a safe and effective drug, having added value because of its analgesic effect and good level of patient adherence. Opportunities for improved PTH1-84 use were identified, such as better patient selection and follow-up based on localization and specialty. Some improvement opportunities were also detected in organizational and educational areas. CONCLUSION: The Forum identified differences between clinical recommendations and daily clinical practice. Some elements, involving both organizational and educational areas that could help to reduce such discrepancies, are described. Springer International Publishing 2012-12-23 2012-12 /pmc/articles/PMC3585953/ /pubmed/23193980 http://dx.doi.org/10.2165/11641360-000000000-00000 Text en © Springer International Publishing AG 2012 |
spellingShingle | Original Research Article Gimeno, Esteban Jódar Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures |
title | Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures |
title_full | Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures |
title_fullStr | Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures |
title_full_unstemmed | Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures |
title_short | Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures |
title_sort | identifying and managing patients at high risk for fractures: conclusions from the second spanish multidisciplinary forum—parathyroid hormone use in osteoporotic patients at high risk for fractures |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585953/ https://www.ncbi.nlm.nih.gov/pubmed/23193980 http://dx.doi.org/10.2165/11641360-000000000-00000 |
work_keys_str_mv | AT gimenoestebanjodar identifyingandmanagingpatientsathighriskforfracturesconclusionsfromthesecondspanishmultidisciplinaryforumparathyroidhormoneuseinosteoporoticpatientsathighriskforfractures |